Published in Biol Chem on March 01, 2007
Isotope-targeted glycoproteomics (IsoTaG): a mass-independent platform for intact N- and O-glycopeptide discovery and analysis. Nat Methods (2015) 1.01
Rapidly evolving marmoset MSMB genes are differently expressed in the male genital tract. Reprod Biol Endocrinol (2009) 0.80
A novel MSMB-related microprotein in the postovulatory egg coats of marsupials. BMC Evol Biol (2011) 0.75
The PSMP-CCR2 interactions trigger monocyte/macrophage-dependent colitis. Sci Rep (2017) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol (2010) 2.26
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem (2006) 1.84
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res (2011) 1.82
Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol (2009) 1.76
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer (2004) 1.63
Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J Leukoc Biol (2010) 1.62
Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruit. J Ethnopharmacol (2002) 1.58
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol (2012) 1.56
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate (2002) 1.54
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol (2003) 1.49
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer (2008) 1.48
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J (2002) 1.47
Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem (2003) 1.45
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res (2005) 1.41
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) (2010) 1.35
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol (2008) 1.35
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate (2009) 1.33
miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer (2010) 1.32
Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer (2009) 1.32
The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol (2010) 1.30
The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res (2008) 1.28
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol (2005) 1.28
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol (2011) 1.27
Microfluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis. Anal Chem (2012) 1.26
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res (2010) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology (2007) 1.21
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst (2008) 1.18
Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod (2002) 1.16